Egan Talmage D
Department of Anesthesiology, University Health Sciences Center, 50 North Medical Dr., 84132, Salt Lake City, UT, USA.
J Anesth. 1998 Dec;12(4):195-204. doi: 10.1007/BF02481730.
Because it is still in its clinical infancy, it is difficult to predict with confidence exactly what role remifentanil will ultimately play in the delivery of anesthesia (and in other settings). It is clear, however, that remifentanil is a new pharmacologic tool with exciting potential that was not possible with the longer-acting opioids. On the basis of its familiar, fentanyl-like pharmacodynamic behavior and its short-acting pharmacokinetic profile, remifentanil may well be advantageous in a variety of settings in which profound opioid effect with subsequent rapid return of spontaneous ventilation and consciousness is desirable. Ongoing research and wide-spread clinical use will be required before the theoretical advantages associated with a short-acting opioid can be fully explored and confirmed.
由于瑞芬太尼仍处于临床应用的初期阶段,因此很难确切地、有把握地预测它最终将在麻醉实施(以及其他情况下)发挥何种作用。然而,很明显,瑞芬太尼是一种具有令人兴奋潜力的新型药理学工具,这是长效阿片类药物所无法实现的。基于其为人熟知的、类似芬太尼的药效学行为以及短效药代动力学特征,瑞芬太尼在各种需要产生深度阿片类效应并随后迅速恢复自主通气和意识的情况下可能具有优势。在与短效阿片类药物相关的理论优势得到充分探索和证实之前,还需要进行持续的研究和广泛的临床应用。